DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

Recruiting now · Not applicable

Conditions studied: DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer

In brief

The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.

Key facts

Study ID

NCT07458906

Run by

The First Affiliated Hospital of Xiamen University

People needed

60

Starts

2025-12-01

Expected to finish

2026-12-31

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (aged 18 years or older);
• Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report);
• Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;
• Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;

You may not qualify if…

• The inability or unwillingness of the research participant or legal representative to provide written informed consent.
• Inability to complete PET/CT imaging.

Where it is running

• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.